AIMEDICS is an Australian Innovative Medical Device Company. Our success is built on the quality of our people and management practices.

AIMEDICS was established in 2001 based on the work and patents of two inventors from the University of Technology Sydney (UTS). Since then, it has been funded through a series of investments and government grants; BIF, NSW Government, Juvenile Diabetes Research Foundation (through UTS) and the Australian Government.

The original technology concepts have been upgraded and developed into the clinically tested HypoMon® product. This first output of the technology platform is targeted as a nocturnal hypoglycaemia monitor and alarm for use by young people with type 1 diabetes. Initial product sales are scheduled to occur in Australia and Europe during 2011.

Our Mission
To successfully market the world’s first non-invasive system which accurately detects and alerts users of sleep-time hypoglycaemia.

Our Purpose
To help people with Insulin Dependent Diabetes Mellitus (IDDM) detect and prevent sleep-time hypoglycemic attacks.

Our Values
1. Exceed customer expectations
2. Scientific & Corporate Integrity
3. Excellence in partnerships
4. Creating shareholder value

Our Vivid Description
AIMEDICS technology is globally accessible to people with IDDM and is recognised as the method to reduce the risk of sleep-time hypoglycaemia.

Our Corporate Governance
The actions of our people are guided by our mission, values and quality management system.

To view our company profile, click here.

To view our board profile, click here.